MED Stock — MEDIFAST INC

MEDIFAST INC (MED)

Updated October 16, 2026.

MED is a Stock. Total return is 185.3% over the past 32.8 years, 2619.5 points behind SPY at 2804.8%.

Medifast Inc. is an equity company in the consumer health and wellness space. The stock does not currently distribute dividends. It may appeal to investors seeking capital appreciation rather than dividend income.

MED performance versus SPY

Price and return data through 2026-10-16.

Total return is 185.3% over the past 32.8 years, 2619.5 points behind SPY at 2804.8%. Over the past year its total return — price change plus distributions reinvested — is -7.6%. Its deepest 1-year drawdown was 28.1%.

MED key facts

Asset type

Stock

Asset class

Equity

Inception date

12/30/1993

Distribution frequency

None

5-year average yield

3.98

Last close

$11.88 (as of 2026-10-16)

Market cap

$132,826,752

Average volume

94126.0

Ex-dividend date

09/18/2023

Payment date

11/07/2023

Beta

0.699

Payout ratio

0.0%

Forward P/E

12.4844

EPS

$-2.33

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MED risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 28.1%.

Who may consider MED — and who may not

It is a weaker fit for investors who need monthly cash flow (MED does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on MED

• All tickers starting with M

Tagged: Consumer Discretionary.

Frequently asked questions